FibroBiologics expands fibroblast therapy portfolio to 170 issued patents
FBLG•FibroBiologics said its portfolio reached 170 issued patents, up from 124 on Dec. 31, 2025. It now has more than 325 issued and pending patents worldwide across over 50 patent families.
1. Patent portfolio grows
FibroBiologics said its fibroblast therapy portfolio has grown to 170 issued patents, up from 124 on Dec. 31, 2025. The company said the portfolio exceeds 325 issued and pending patents worldwide across more than 50 patent families, with more than 150 applications still pending.
2. Recent patent areas
U.S. patents granted in 2026 cover wound healing, type 1 diabetes and other diseases. European grants protect methods to enhance fibroblast therapeutic activity and deliver tumor-inhibiting agents; recent filings include injectable thymus organoids, therapeutic peptide-producing cell aggregates and oral fibroblast therapies.
